Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.com

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Friday.

Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. UBS Group began coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a "buy" rating and a $37.00 target price for the company. The Goldman Sachs Group boosted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Bank of America increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, August 15th. Finally, Barclays boosted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an "overweight" rating in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $36.00.

Syndax Pharmaceuticals Trading Down 5.7 %

Shares of NASDAQ SNDX traded down $0.96 during trading on Friday, reaching $15.83. 5,023,028 shares of the company traded hands, compared to its average volume of 1,128,477. The stock has a market cap of $1.35 billion, a P/E ratio of -4.36 and a beta of 0.92. The firm's fifty day simple moving average is $18.94 and its 200 day simple moving average is $20.25. Syndax Pharmaceuticals has a 12-month low of $14.50 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter last year, the company posted ($0.73) EPS. As a group, research analysts expect that Syndax Pharmaceuticals will post -3.61 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently modified their holdings of SNDX. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth $27,000. Values First Advisors Inc. purchased a new position in Syndax Pharmaceuticals in the 3rd quarter valued at about $30,000. nVerses Capital LLC acquired a new stake in Syndax Pharmaceuticals during the second quarter worth approximately $33,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $49,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after buying an additional 541 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.